TY - JOUR
T1 - Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia
AU - Patnaik, Mrinal M.
AU - Barraco, Daniela
AU - Lasho, Terra L.
AU - Finke, Christy M.
AU - Reichard, Kaaren
AU - Hoversten, Katherine P.
AU - Ketterling, Rhett P.
AU - Gangat, Naseema
AU - Tefferi, Ayalew
N1 - Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2017/6
Y1 - 2017/6
N2 - Atypical chronic myeloid leukemia (aCML) is an aggressive myeloid neoplasm with overlapping features of myelodysplastic syndromes (prominent granulocytic dysplasia) and myeloproliferative neoplasms (neutrophilic leukocytosis). We studied 25 molecularly-annotated and World Health Organization defined aCML patients; median age 70 years, 84% males. Cytogenetic abnormalities were seen in 36% and gene mutations in 100%. Mutational frequencies were, ASXL1 28%, TET2 16%, NRAS 16%, SETBP1 12%, RUNX1 12%, ETNK1 8%, and PTPN11 4%. Fifteen patients (60%) had >1 mutation, while 9 (36%) had ≥3. The median overall survival (OS) was 10.8 months and at last follow up (median 11 months), 17 (68%) deaths and 2 (8%) leukemic transformations were documented. On univariate analysis, survival was adversely impacted by advanced age (P =.02), low hemoglobin (P =.01), red blood cell transfusion dependence (P =.03), high white blood cell count (P =.02), TET2 (P =.03), NRAS (P =.04), PTPN11 (P =.02) mutations and the presence of ≥3 gene mutations (P =.006); ASXL1, SETBP1, and ETNK1 mutations did not impact OS. In multivariable analysis, advanced age (P =.003) [age >67: HR 10.1, 95% CI 1.3-119], low hemoglobin (P =.008) [HB< 10 gm/dL: HR 8.2, 95% CI 1.6-23.2] and TET2 mutations (P =.01) [HR 8.8, 95% CI 1.6-47.7] retained prognostic significance. We then used age >67 years, hemoglobin <10 gm/dL and the presence of TET2 mutations (each counted as one risk factor) to create a hazard ratio weighted prognostic model; effectively stratifying patients into two risk categories, low (0-1 risk factor) and high (≥2 risk factors), with median OS of 18 and 7 months, respectively.
AB - Atypical chronic myeloid leukemia (aCML) is an aggressive myeloid neoplasm with overlapping features of myelodysplastic syndromes (prominent granulocytic dysplasia) and myeloproliferative neoplasms (neutrophilic leukocytosis). We studied 25 molecularly-annotated and World Health Organization defined aCML patients; median age 70 years, 84% males. Cytogenetic abnormalities were seen in 36% and gene mutations in 100%. Mutational frequencies were, ASXL1 28%, TET2 16%, NRAS 16%, SETBP1 12%, RUNX1 12%, ETNK1 8%, and PTPN11 4%. Fifteen patients (60%) had >1 mutation, while 9 (36%) had ≥3. The median overall survival (OS) was 10.8 months and at last follow up (median 11 months), 17 (68%) deaths and 2 (8%) leukemic transformations were documented. On univariate analysis, survival was adversely impacted by advanced age (P =.02), low hemoglobin (P =.01), red blood cell transfusion dependence (P =.03), high white blood cell count (P =.02), TET2 (P =.03), NRAS (P =.04), PTPN11 (P =.02) mutations and the presence of ≥3 gene mutations (P =.006); ASXL1, SETBP1, and ETNK1 mutations did not impact OS. In multivariable analysis, advanced age (P =.003) [age >67: HR 10.1, 95% CI 1.3-119], low hemoglobin (P =.008) [HB< 10 gm/dL: HR 8.2, 95% CI 1.6-23.2] and TET2 mutations (P =.01) [HR 8.8, 95% CI 1.6-47.7] retained prognostic significance. We then used age >67 years, hemoglobin <10 gm/dL and the presence of TET2 mutations (each counted as one risk factor) to create a hazard ratio weighted prognostic model; effectively stratifying patients into two risk categories, low (0-1 risk factor) and high (≥2 risk factors), with median OS of 18 and 7 months, respectively.
UR - http://www.scopus.com/inward/record.url?scp=85018959201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018959201&partnerID=8YFLogxK
U2 - 10.1002/ajh.24722
DO - 10.1002/ajh.24722
M3 - Article
C2 - 28314085
AN - SCOPUS:85018959201
SN - 0361-8609
VL - 92
SP - 542
EP - 548
JO - American journal of hematology
JF - American journal of hematology
IS - 6
ER -